Dr. David Bearss, a serial entrepreneur and pharmaceutical innovator, dives into Halia Therapeutics' pioneering efforts against Alzheimer’s disease. He shares personal motivations stemming from family health struggles and discusses the impressive shift in focus from cancer research to combating neuroinflammation. Bearss highlights the unique challenges biotech startups face, stressing the importance of adaptability and a strong team culture. He also reflects on strategic partnerships crucial for innovative drug development, revealing insights into the future of healthcare.